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By preventing access of drugs to the CNS, the blood^brain barrier hampers developments in brain pharma-
cotherapy. Strong efforts are currently being made to identify drugs that accumulate more efficaciously in
ischaemic brain tissue.We identified an ATP-binding cassette (ABC) transporter, ABCC1, which is expressed
on the abluminal surface of the brain capillary endothelium andmildly downregulated in response to focal cere-
bral ischaemia, induced by intraluminalmiddle cerebral artery occlusion. In biodistribution studies we show that
ABCC1 promotes the accumulation of known neuroprotective and neurotoxic compounds in the ischaemic and
non-ischaemic brain, ABCC1 deactivation reducing tissue concentrations by up to two orders of magnitude. As
such, ABCC1’s expression and functionality in the brain differs from the liver, spleen and testis, where ABCC1 is
strongly expressed on parenchymal cells, resultingçin case of liver and testisçin directed transport from the
tissue into the blood. After focal cerebral ischaemia, ABCC1 deactivation abolished the efficacy of both neuro-
protective and neurotoxic compounds.Our data indicate that ABCC1acts as gateway for pharmacological com-
pounds to the stroke brain.We suggest that the tailoring of compounds binding to abluminal but not luminal
ABC transporters may facilitate stroke pharmacotherapy.
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Introduction
Pharmacological therapies have made limited progress in the
brain recently (Lo¨scher and Potschka, 2005; Hermann et al.,
2006). As such, many candidate drugs evaluated in clinical
trials have failed, particularly in ischaemic stroke (O’Collins
et al., 2006; Hermann and Bassetti, 2007). A major obstacle
for newly developed compounds is the blood–brain barrier
(BBB), which prevents systemically administered molecules
from entering the brain (Pardridge, 2002; Begley, 2004). The
BBB acts not only as passive diffusion barrier. It expresses
active transporters that eliminate drugs from the brain
tissue (Lo¨scher and Potschka, 2005; Hermann et al., 2006).
Strong efforts have been made in recent years to iden-
tify pharmacological compounds that accumulate more
efficaciously in the diseased brain. As such, the physicochem-
ical properties of compounds (e.g. lipophilicity, surface
charges, molecular size), their uptake via receptor-dependent
or -independent endocytosis, as well as their binding to
membrane-bound ATP-binding cassette (ABC) transporters
and solute carriers were recognized to influence drug accu-
mulation (Begley, 2004; Hermann et al., 2006).
In contrast to solute carriers, which are bi-directional,
low-affinity transporters driven by concentration gradients
of endogenous molecules (e.g. carnithine, urate, Na+, H+),
carrying organic compounds through cell membranes both
in an inward and outward direction (Meier and Stieger,
2002; Hagenbuch and Meier, 2004), ABC transporters
are unidirectional high-affinity pumps eliminating a broad
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variety of chemically unrelated lipophilic and amphipathic
molecules from cells in an ATP-dependent manner
(Higgins et al., 1986; Lo¨scher and Potschka, 2005), among
which there are many pharmacological compounds.
ABC transporters have received considerable interest in
the brain recently, since they impede the brain accumu-
lation of drugs. In fact, most ABC transporters, such as
their best-characterized member ABCB1 [previously called
multi-drug resistance transporter (Mdr)-1], are abundantly
expressed on the luminal membrane of brain capillary cells
(Lo¨scher and Potschka, 2005; Hermann and Bassetti, 2007).
As a consequence, these transporters extrude drugs from
the brain back into the blood (Rizzi et al., 2002; Lo¨scher
and Potschka, 2005; Spudich et al., 2006).
Not all ABC transporters exhibit luminal endothelial
expression. For the transporter ABCC1 [formerly multi-
drug resistance-associated protein (Mrp)-1], it was recently
demonstrated that this transporter is predominantly expres-
sed on the abluminal endothelial membrane (Soontornmalai
et al., 2006). Similar to ABCB1, ABCC1 reveals strong binding
affinity to many amphipathic compounds (Hermann and
Bassetti, 2007). Besides, ABCC1 also binds glucuronidated,
glutathionized and sulphated molecules, which are not
ABCB1 substrates (Hermann and Bassetti, 2007).
Until now, the relevancy of ABCC1 for pharmacological
therapies remained unknown. Using immunohistochemical
studies, Western blots with capillary-enriched brain tissue
fractions and experiments, in which we deactivated ABCC1
by pharmacological inhibition or genetic knockout, we now
examined the role of ABCC1 in the ischaemic brain,
analysing its effect on drug accumulation and efficacy after
middle cerebral artery (MCA) occlusion.
Methods
Focal cerebral ischaemia
Experiments were performed in accordance to National Institutes
of Health (NIH) guidelines for the care and use of laboratory
animals and approved by local government authorities
(Kantonales Veterina¨ramt; ZH169/2005). Male C57Bl6/j mice as
well as male abcc1–/– mice, produced on a FVB.129P2 background
(Taconic, New York, USA) together with abcc1+/+ controls, were
used. At the age of 8–10 weeks (animal weight: 20–23 g), animals
were anaesthetized with 1% isoflurane (30% O2, remainder N2O).
Rectal temperature was maintained between 36.5C and 37.0C,
and laser Doppler flow (LDF) was monitored with a flexible
fiberoptic probe that was placed above the core of the MCA
territory (Perimed, Stockholm, Sweden) (Wang et al., 2005; Kilic
et al., 2006). Focal cerebral ischaemia was induced by intraluminal
MCA occlusion, as previously described (Wang et al., 2005;
Kilic et al., 2006). Sham animals received neck incisions, in which
the common carotid artery was isolated, but not ligated or cut.
At indicated times (specified below), in case of sham animals after
3 h reperfusion, animals were re-anaesthetized and transcardially
perfused with normal saline [immunohistochemistry/Western
blots; liquid chromatography/mass spectrometry (LC-MS) for
the ABCC1 substrate 17b-estradiol-17b-D-glucuronide (17bEG)]
or killed by decapitation [LC-MS for the ABCC1 substrate
S-nitrosoglutathione (GSNO); drug-efficacy studies]. Brains,
liver, spleen and testis were removed, frozen and cut into coronal
18 mm cryostat sections for immunohistochemistry of ABC
transporters, terminal transferase biotinylated-dUTP nick end
labelling (TUNEL) or cresyl violet staining. Tissue samples were
also taken from both MCA territories (lateral parietal cortex and
underlying striatum), the liver, spleen and testis for Western
blots and LC-MS.
Immunohistochemistry for ABCC1 and other
multi-drug transporters
Cryostat sections from mice submitted to sham surgery (3 h
survival) or to 30 or 90min of MCA occlusion (3 h reperfusion)
(n=5 animals per group) were fixed in 4% paraformaldehyde in
0.1M phosphate-buffered saline (PBS), blocked in 0.1M PBS
containing 0.3% Triton-X-100 (PBS-T) and 10% normal goat
serum (NGS) and incubated overnight at 4C with polyclonal guinea
pig anti-mouse ABCC1 (clone J95 ESD8; Institute of Pharmacology
and Toxicology, University of Zurich), polyclonal rabbit anti-human
ABCB1 (H-241, sc-8313; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), polyclonal rabbit anti-mouse ABCC2 (clone J81 ESD2;
Institute of Pharmacology and Toxicology), polyclonal rabbit
anti-rat ABCC3 (clone J81 ESD3; Institute of Pharmacology and
Toxicology) or monoclonal rat anti-human ABCC5 (ALX801021-
C250 or ALX801022-C250; Alexis, Lausen, Switzerland) antibody,
diluted 1 : 100 in 0.1M PBS-T containing 2% NGS. Sections were
counterlabelled with rat or goat anti-CD31 (BD Biosciences, Basle,
Switzerland), mouse anti-NeuN (MAB377; Chemicon, Lucerne,
Switzerland) or rabbit anti-GFAP (Dako, Zug, Switzerland)
antibody. The specificity of the ABCC1, ABCB1, ABCC2, ABCC3
and ABCC5 antibodies in the brain has previously been shown
(Soontornmalai et al., 2006; Spudich et al., 2006). In fact, negative
controls, in which antibodies were omitted, did not result in any
staining (data not shown). As positive controls, liver and kidney
sections were used (Soontornmalai et al., 2006). Sections were
evaluated microscopically by a blinded investigator. ABCC1
expression levels were evaluated by counting densities of ABCC1+
capillaries in a total of six rectangular random regions of interest
(ROI) in the ischaemic and non-ischaemic striatum, each 1mm
apart, and additional six random ROI in the parietal cortex, 600mm
apart, each ROI measuring 62 500mm2 (Spudich et al., 2006).
Western blots for ABCC1
Ten micrograms of enriched microvessel protein (for preparation
see Spudich et al., 2006) obtained from pooled tissue samples of
C57Bl6/j mice submitted to sham surgery (3 h survival), 30min
(3, 24 or 72 h reperfusion) or 90min (3, 12 or 24 h reperfusion)
of MCA occlusion (n= 5 animals per group) were subjected to
sodium dodecylsulphate–polyacrylamide gel electrophoresis (SDS–
PAGE) and transferred onto polyvinylidene fluoride (PVDF)
membranes. After blocking, membranes were incubated in a
monoclonal rat antibody that specifically recognizes ABCC1
(ALX801007, Alexis; diluted 1:100 in 0.1% TBS-T containing 5%
milk). Following incubation in peroxidase-coupled secondary
antibody, membranes were immersed in enhanced chemolumines-
cence (ECL) solution and exposed to ECL-Hyperfilm (Amersham,
Otelfingen, Switzerland). Protein loading was controlled with
a mouse anti-b-actin antibody (Sigma-Aldrich). Blots revealed a
190 kDa band that was absent in control studies in which the
primary antibody was omitted. Blots were digitized, ABCC1 levels
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densitometrically analysed, corrected for protein loading and
expressed as relative values compared with ABCC1 levels in sham-
operated mice.
Effects of ABCC1 inhibition on the brain
accumulation of 17bEG and GSNO
To evaluate how ABCC1 deactivation affects drug accumulation in
the brain, we used a pharmacological inhibition strategy using
MK571 (Alexis, Lausen, Switzerland), a potent ABCC1 blocker
(Kimura et al., 2005). Two different ABCC1 substrates were
assessed, namely 17bEG (Sigma-Aldrich) (Cisternino et al., 2003)
and GSNO (WPI Europe, Berlin, Germany) (Khan et al., 2005).
To evaluate drug accumulation in the brain, C57Bl6/j mice
submitted to 30min MCA occlusion were treated via the femoral
vein with either vehicle (0.9% NaCl) or MK571 (10mg kg–1 body
weight, dissolved in 0.9% NaCl), 60min later followed by 17bEG
(10mg kg–1, in 0.9% NaCl) (n= 5–7 animals per group) or GSNO
(1mg kg–1, in 0.9% NaCl) (n= 4 animals per group). Two hours
(in case of 17bEG) or 2min (in case of GSNO) later, blood
samples were collected in vials coated with lithium heparinate
(Vacutainer; Becton Dickinson, Basle, Switzerland) and animals
were sacrificed. The time point of 2min in case of GSNO was
chosen in view of the high instability of this NO donor. In a first
set of studies, in which animals were killed 15min or 2 h after
GSNO infusion, brain levels have been close to or even below
detection limits (data not shown). In the plasma and brain sam-
ples obtained, 17bEG, its deglucuronidated parent compound
17b-estradiol (17bE) and GSNO were analysed by LC-MS.
Similarly, 17bEG and 17bE levels were determined by LC-MS in
the animals’ liver, spleen and testis.
LC-MS for 17bEG and 17bE
Weighted tissue samples were homogenized in 0.9% NaCl and
divided into three portions as follows: In portion 1, the con-
centration of 17bE was quantified by the addition of 2.5 pmol
17bE-d3 (Sigma-Aldrich) in 50 ml 90% (v/v) ethanol and 50 ml
phosphate buffer (50mM, pH 7.0). After extraction with 3ml
dichloromethane, separation of the organic phase and evaporation
of the solvent, 17bE and 17bE-d3 in the residue was derivatized by
adding 50 ml carbonate buffer (100mM, pH 10.5) and 50 ml dansyl
chloride in acetone (1mgml–1) for 3min at 60C. After cooling
to room temperature, the solution was directly injected into the
high-performance liquid chromatography (HPLC) system. In por-
tion 2, the total amount of 17bE and 17bEG was quantified by the
addition of 2.5 pmol 17bE-d3 in 90% (v/v) ethanol and 50 ml
(1000U) b-glucuronidase (Sigma-Aldrich) in phosphate buffer.
The deglucuronidation was performed for 1 h at 37C. In portion
3, 2.5 pmol 17bE in 50 ml phosphate buffer pH 7.0 and 2.5 pmol
17bEG-d3 in 90% (v/v) ethanol were added to enable tissue
quantification of 17bE. The extraction and derivatization in
portions 2 and 3 were identical as described for portion 1. The
extraction and derivatization of plasma was identical as that for
tissue samples. For analysis, 50 ml plasma were complemented with
2.5 pmol 17bE-d3 in 50ml 90% (v/v) ethanol, 50 ml phosphate
buffer pH 7.0 and 200 ml 0.9% NaCl.
The dansylated 17bE was analysed by the LC-MS/MS
system consisting of a Rheos 2000 pump (Flux Instruments, Basle,
Switzerland), a PAL autosampler (CTC Analytics, Zwingen,
Switzerland) and a LCQ TSQ 7000 (ThermoQuest, San Jose, CA,
USA) using selected reaction monitoring. An Uptisphere 5 ODB
column (125 2mm; Interchim, Montluc¸on, France) was used.
The mobile phase was a gradient of water/acetonitrile (95/5, v/v)
against water/acetronitrile/methanol (5/30/65, v/v) containing 0.1%
formic acid. The flow rate was also run as a gradient between 0.2
and 0.3ml min–1. The ionization mode was positive atmospheric
pressure chemical ionization. The vaporizer temperature and capil-
lary temperature were kept at 450C and 250C, respectively, the
discharge current fixed at 6 mA. The sheath gas pressure was held at
60 psi, the auxiliary gas pressure at 15 psi, respectively. The tissue
concentration of 17bE was calculated using the standard addition
method. Standard curves for 17bE in plasma were linear with a
correlation coefficient of50.999 and the coefficients of variations
56%. With the concentrations determined, tissue-to-plasma con-
centration ratios were calculated, which were expressed—unless
otherwise specified—as pmol g–1 (tissue) per pmol ml–1 (plasma).
LC-MS for GSNO
Weighted tissue samples were homogenized with 30mM ammo-
nium sulphamate in 0.9% NaCl solution containing 0.4% sodium
fluoride. To brain homogenates and plasma samples, ammonium
sulphamate (30mM) in 0.9% NaCl was added to remove endoge-
nous nitrite. One-hundred picomole [15N]-GSNO, synthesized by
S-nitrosylation of GSH with acidified [15N]-NaNO2 (Dr Glaser,
Basle, Switzerland), was used as internal standard. Proteins were
precipitated with 30mM ammonium sulphamate and 10% trichlo-
roacetic acid (TCA) in water and the precipitate was centrifuged at
20 000g for 10min at 5C. The supernatants were neutralized with
4M dipotassium hydrogenphosphate to pH 6.0, mixed with 1M
borate buffer to final pH 7.5-8.0 and derivatized for 1min with
15.5mM 9-fluorenylmethyl chloroformate (FMOCCl; Fluka,
Buchs, Switzerland) in acetone at room temperature. The excess
of FMOCCl was removed by extracting with 2ml n-pentane.
The FMOC-GSNO in the aqueous phase was analysed by the
LC-MS/MS system (analytical instrumentation as above) under an
elution gradient of water/acetonitrile (95/5, v/v) containing 0.1%
formic acid against water/acetronitrile/methanol (5/30/65, v/v)
containing 0.1% formic acid. The flow rate was 0.3ml min–1. The
capillary temperature was kept at 250C, the electrospray voltage
at 5 kV (negative ionization). The sheath gas pressure was held at
60 psi, the collision gas (argon) pressure at 1.30 mTorr, respec-
tively. Standard curves for GSNO in plasma were linear with a
correlation coefficient of 50.999. Coefficients of variation for
the LC-MS assay were 56%. The concentrations of GSNO in
brain homogenates were determined using the standard addition
method. Tissue-to-plasma concentration ratios were calculated
and expressed as pmol g–1 (tissue) per pmol ml–1 (plasma).
Effects of ABCC1 deactivation on ischaemic
brain injury
The protocol of the drug efficacy studies is summarized in
Supplementary Fig. 1. Two different ABCC1 deactivation strategies
were used in mice subjected to 30 or 90min MCA occlusion,
namely pharmacological inhibition with MK571 and genetic
abcc1–/–. Animals undergoing 30min MCA occlusion were intra-
peritoneally treated with vehicle (0.9% NaCl) or MK571 (10mg
kg–1 body weight, as above) immediately after reperfusion and
at 24 and 48 h after stroke. Always 60min later, either vehicle
(0.9% NaCl), 17bEG (2, 5, 10 or 50mg kg–1 body weight, as
above) or GSNO (0.2, 0.5, 1 or 5mg kg–1 body weight, as above)
were intraperitoneally applied (n= 7–8 animals per group).
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Animals were sacrificed 72 h after reperfusion onset. Mice
subjected to 90min of MCA occlusion were intraperitoneally
treated with either vehicle or MK571 (10mg kg–1 body weight, as
above) immediately after reperfusion, 10min later followed by
vehicle, 17bEG (2 or 10mg kg–1 body weight, as above) or GSNO
(0.2 or 1mg kg–1 body weight, as above) (n=6–8 animals per
group). These animals were killed 24 h following stroke.
Analysis of histological brain injury
Brain sections from the level of the mid-striatum (bregma
0.0mm) of animals submitted to 30min MCA occlusion were
fixed with 4% paraformaldehyde in 0.1M PBS and stained by
TUNEL using a commercially available kit (Roche, Basle,
Switzerland). In these sections, DNA fragmented cells were
counted in blinded manner in six random ROI in the striatum
(1mm apart), and six random ROI in the cortex (600 mm apart),
each measuring 62 500 mm2. These ROI were chosen as 30min
MCA occlusion usually leads to disseminate neuronal damage in
the mouse striatum (Wang et al., 2005; Spudich et al., 2006),
which may expand into the cortex under conditions of exacer-
bated brain injury. In fact, exclusively striatal DNA fragmentation
was seen in our present studies in case of most vehicle-treated or
17bEG-treated animals, whereas GSNO delivered at doses of 1 or
5mg kg–1 reproducibly resulted also in cortical cell death. Animals
subjected to 90min MCA occlusion were analysed by staining
a total of four sections from equidistant brain levels, 2mm apart
(starting from the rostral pole of the striatum: bregma +2.0mm,
followed by sections at levels bregma 0.0, –2.0 and –4.0mm) with
cresyl violet. Brain infarcts were outlined on these sections by
delineating non-lesioned tissue in both hemispheres, thereby
determining oedema-corrected infarct areas, and subsequently
calculating infarct volumes (Wang et al., 2005; Kilic et al., 2006).
Statistics
Results are presented as means SD. Data were analysed by one-
way ANOVA followed by least significant differences (LSD) tests
(comparisons between 53 independent groups), repeated mea-
surement ANOVA (comparisons between 54 groups including
within-subject comparisons), two-way ANOVA (comparisons
between four independent groups elucidating drug interactions)
or unpaired two-tailed t-tests (comparisons between two groups),
using SPSS for Windows 12.0.1. In case of multiple comparisons
being made, significance levels were adapted using Bonferroni
corrections. P-values50.05 were considered significant.
Results
Distribution of ABCC1 in the brain and
in peripheral tissues
In immunohistochemistries we observed that ABCC1 is
expressed on the brain capillary endothelium of C57Bl6/j
and FVB mice, where ABCC1 was almost exclusively found
on the abluminal surface (Fig. 1). On the other hand, ABCC1
was undetectable on neurons or glial cells throughout the
brain (Fig. 1). Thus, ABCC1 expression in the brain differed
from peripheral tissues, where ABCC1 immunoreactivity
was noticed on parenchymal cells and—in case of spleen and
testis—vascular staining was faint (Fig. 2).
In the brain, ABCC1 levels were mildly reduced in
response to focal cerebral ischaemia (Fig. 1). Western blots
using enriched brain microvessel fractions revealed that
ABCC1 expression decreased at 3 h and partly recovered
within 24 to 72 h after stroke (Fig. 3).
Effect of ABCC1 inhibition on tissue
accumulation of 17bEG and GSNO
To analyse how ABCC1 influences drug accumulation after
stroke, we blocked ABCC1 in C57Bl6/j mice with MK571
(10mg kg–1) and concomitantly delivered the ABCC1
substrates 17bEG (10mg kg–1) or GSNO (1mg kg–1).
Notably, ABCC1 deactivation decreased the brain-to-plasma
concentration ratio of 17bEG and GSNO both in the
ischaemic and non-ischaemic tissue by more than two
orders of magnitude (P50.001; Fig. 4), as shown by LC-MS.
Following 17bEG delivery, the brain content not only of
17bE’s 17b-D-glucuronide, but also its deglucuronidated
parent compound 17bE was reduced (Fig. 4, P50.05), as
our LC-MS studies revealed.
ABCC1’s transport function in the brain differed from
the liver and testis, where ABCC1 deactivation mildly
increased 17bEG and—in case of liver—also 17bE levels
(P50.05; Table 1). In the spleen, 17bEG and 17bE levels
were not influenced by MK571 (Table 1).
Blood levels of 17bEG and GSNO remained unchanged
after ABCC1 deactivation (Fig. 4). Blood levels of 17bE
were low in both groups {log10[concentration(pmol ml–1)]:
0.32 0.62 versus 1.10 1.32 in vehicle versus MK571-
treated mice}.
Effect of ABCC1 inhibition on survival
effects of 17bEG and GSNO
To clarify whether ABCC1 inhibition attenuates the survival
effects of 17bEG and GSNO, we again deactivated ABCC1 in
ischaemic C57Bl6/j mice with MK571 and subsequently
applied both drugs at various dosages. Experiments in
animals submitted to 30 or 90min MCA occlusion consis-
tently showed attenuation both of 17bEG neuroprotection
and GSNO neurotoxicity following ABCC1 blockade (Figs 5
and 6). As such, drug effects were almost abolished even at
doses 10 times above the therapeutic threshold (Figs 5 and 6).
To evaluate the specificity of our pharmacological obser-
vations, we subsequently examined the effects of 17bEG and
GSNO in abcc1–/– mice produced on a FVB background.
Blunted drug responses in abcc1–/– as compared with
abcc1+/+ animals confirmed that the changes noticed after
pharmacological transporter blockade were indeed linked
to ABCC1 (Fig. 5).
In abcc1–/– mice, expression patterns of ABCB1, ABCC2,
ABCC3 and ABCC5 were identical to abcc1+/+ animals.
Thus, ABCC2 and ABCC3, which also bind glucuronidated
and/or glutathionized compounds (Lo¨scher and Potschka,
2005), were absent and ABCB1 and ABCC5, which bind
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Fig. 1 ABCC1 is expressed on brain capillaries on the abluminal surface between the luminal membrane (CD31) and astrocytic endfeet
(GFAP). Confocal laser scanning microphotographs showing ABCC1 in ischaemic vessels 3h after 30min MCA occlusion (A and B).
Note the absence of ABCC1 in the brain parenchyma, i.e. on neurons (NeuN) and astrocytes (GFAP). The quantitative analysis of
vessel densities in the cortex and striatum of mice submitted to 30min (C) and 90min (D) MCA occlusion reveals reduced ABCC1 levels
at 3h following stroke. Data from C57Bl6/j mice are shown. Data are means SD (n=5 per group, repeated measurement ANOVA,
time effects are shown, and t-tests). P50.05/P50.01 compared with contralateral sham. Bar=30mm.
Fig. 2 ABCC1distribution in the liver, spleen and testis differs from the brain. Immunohistochemistries revealing abundant ABCC1
expression (A) in the liver on CD31ç hepatocytes (hc) andçslightly less intenseçon endothelial cells of a central vein (cv), (B) in the
spleen on CD31ç cells of the white pulp (wp), but not on CD31+ central arteries (ca) and CD31ç red pulp (rp), and (C) in the testis
on spermatids (sp) and seminiferous tubules (st). Sections from C57Bl6/j mice are shown. Bar=100mm (left)/50mm (right).
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unconjugated but not conjugated molecules (Lo¨scher and
Potschka, 2005), were expressed at similar levels in both
mouse lines (Supplementary Fig. 2).
Discussion
While the role of ABC transporters in drug elimination is
well established in many diseases, including stroke, epilepsy
and brain cancer (Lo¨scher and Potschka, 2005; Hermann
et al., 2006), we for the first time provide evidence
that an ABC transporter, ABCC1, actively promotes the
accumulation and efficacy of pharmacological compounds
in the ischaemic brain. As such, the profoundly reduced
tissue levels, which were more than 100-fold below control
conditions when ABCC1 was deactivated, suggest that drug
accumulation may be more strongly than previously
thought an active process. As ABCC1 is a broad-spectrum
transporter, which binds a large variety of chemically
unrelated substrates (Hermann and Bassetti, 2007), ABCC1
might offer itself as vehicle for drug delivery purposes. It is
noteworthy that ABCC1 was still functional in the brain
after ischaemia, despite the fact that ABCC1 levels were
mildly reduced. ABCC1’s retained functionality exemplifies
its importance for drug biodistribution processes.
Transport activity attributed
to expression pattern
ABCC1’s role at the BBB profoundly differs from the liver,
spleen and testis. In the liver and testis, ABCC1 deactivation
mildly increased levels of the ABCC1 substrate 17bEG, just
opposite to our findings in the brain. The specificities of
pharmacological transport are attributed to differences in
ABCC1 expression. As such, the abluminal endothelial
expression of ABCC1 at the polarized BBB explains why
the transporter promotes molecular uptake into the brain.
On the other hand, parenchymal expression provides a
rationale for ABCC1’s role in drug removal in peripheral
tissues. On the cellular level, ABC transporters act as ATP-
dependent efflux pumps carrying drugs from the intra-
cellular towards extra-cellular space. This directional
transport was recently confirmed using crystal structures
of ABC transporter molecules (Murakami et al., 2006). It
was also shown for ABCC1 in in vitro studies, in which
ABCC1 was deactivated by pharmacological blockade,
small-interfering RNA or genetic knockout (Regina et al.,
1998; Seetharaman et al., 1998; Mu¨ller et al., 2005).
ABCC1 expression in the brain had been a matter of debate
previously. In vitro studies with rodent, bovine and human
brain microvessels reported ABCC1 expression on endothe-
lial cells and astrocytes (Regina et al., 1998; Seetharaman
et al., 1998; Berezowski et al., 2004). Importantly, ABCC1
levels increased with cell culturing, suggesting that its role
in vivo differs from in vitro (Regina et al., 1998; Seetharaman
et al., 1998). ABCC1 has been observed on astrocytes in
models of drug-refractory epilepsy (Dombrowski et al., 2001;
van Vliet et al., 2005). In drug-refractory epilepsy, several
ABC transporters are induced (van Vliet et al., 2005). As such,
this condition is not representative for the healthy brain.
In healthy rodents, ABCC1 was found exclusively on brain
capillaries but not astrocytes (Soontornmalai et al., 2006).
Our data presented here after ischaemia confirm these find-
ings. In Western blots, we have never been able to detect
ABCC1 in whole-brain homogenates (data not shown), but
only in capillary-enriched fractions. We conclude that ABCC1
is not expressed in the brain parenchyma to relevant extent.
We did not observe ABCC2 expression on brain capillaries
of FVB mice. The lack of ABCC2 expression is in line with
Fig. 3 ABCC1 expression decreases in response to focal cerebral
ischaemia.Western blot analysis exhibiting the 190kDa ABCC1
protein in enriched microvessel fractions of brains from sham-ani-
mals and animals submitted to 30min (A) or 90min (B) MCA
occlusion, followed by 3^72h reperfusion. Note that ABCC1 levels
declines already 3h after ischaemia both in ischaemic and contral-
ateral injury-remote tissue, recovering partly within 72h after
30min MCA occlusion. Data were analysed densitometrically and
corrected for protein loading assessed on b-actin blots. Control
experiments, in which the primary antibody was omitted, did not
reveal any signal (data not shown).Capillary extracts from C57Bl6/j
mice were used.Values are means SD (n=3 different blots per
group). Data were evaluated by repeated measurement ANOVA
(time effects shown) and t-tests. P50.05/P50.01 compared with
contralateral sham.
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previous studies, which also did not localize ABCC2 on brain
capillaries in this mouse line (Soontornmalai et al., 2006). As
such, ABCC2’s expression in FVB mice differs from C57Bl6/j
mice (Soontornmalai et al., 2006) and rats (van Vliet et al.,
2005), where ABCC2 expression was previously reported.
Choice of ABCC1 substrates
To evaluate the functionality of ABCC1, we chose two
compounds, 17bEG and GSNO, which are known sub-
strates of ABCC1 but not ABCB1 and which we considered
both to be neuroprotective after stroke. In case of 17bE,
survival-promoting actions are well established after focal
cerebral ischaemia (Yang et al., 2000; Rau et al., 2003).
In case of GSNO, neuroprotective effects had also been
described in a rat model of ischaemic stroke (Khan et al.,
2005). We were surprised that GSNO exacerbated brain
injury in mice after MCA occlusion. GSNO acts as NO
donor, which promotes the reactivity of brain arterioles,
but exacerbates neuronal injury via free radical formation
(Dalkara and Moskowitz, 1994; Chan, 2001). Neuronal
effects most likely explain the injury-aggravating effect of
GSNO. Since we used 17bEG and GSNO as model
compounds and were not interested in their mechanisms
of action, the fact that GSNO increased ischaemic injury
was of minor importance for our studies.
Considerations regarding earlier
biodistribution studies
Previous reports had not been unambiguous about the role
of ABCC1 in drug distribution. As such, an involvement of
ABCC1 in drug elimination had been suggested following
17bEG and GSNO delivery in some (Nishino et al., 1999;
Fig. 4 Pharmacological inhibition of ABCC1with MK571dramatically reduces the brain accumulation of17bEG and GSNO in C57Bl6/j mice.
Plasma concentrations (A andD) and brain-to-plasma concentration ratios (B,D and E) for17bEG, its parent17bE and GSNO, analysed by
LC-MS in mice submitted to focal cerebral ischaemia induced by 30min MCA occlusion.Data are means SD [n=5^7 per group (A and B),
n=4 per group (C and D)]. Repeated measurement ANOVA and t-tests (drug effects are shown). P50.05/P50.01 compared with ani-
mals receiving 17bEG (10mg kg^1) or GSNO (1mg kg^1) only.
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Table 1 Tissue-to-plasma concentration ratios of 17bEG and 17bE in the liver, spleen and testis (in pmol mg1 per pmol ml1)
17bEG 17bE
Liver Spleen Testis Liver Spleen Testis
17bEG 6.012.03 1.35 0.45 0.60 0.15 251.98134.40 19.469.74 5.57 2.11
MK571/17bEG 32.49 25.90 1.04 0.25 0.89 0.29 810.00333.40 23.6612.54 9.835.28
P50.05 compared with animals receiving 17bEG only (unpaired t-tests). n=7 animals per group.
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Fig. 5 Deactivation of ABCC1 abolishes 17bEG’s neuroprotective and GSNO’s neurotoxic effects after focal cerebral ischaemia induced by
30min MCA occlusion. LDF measurements during and after ischaemia (A and C) and disseminate cell death evaluated by terminal trans-
ferase biotinylated-dUTP nick end labelling (TUNEL; green fluorescence) 72h after reperfusion (B and D). Note the absence of blood flow
changes between groups (A and C). Furthermore note that deactivation of ABCC1 by pharmacological blockade in C57Bl6/j mice and
abcc1^/^ in FVB mice almost completely reverses drug effects on ischaemic injury (B and D). Representative microphotographs forTUNEL
stainings showing DNA-fragmented cells in the striatum are also presented. Data are means SD (n=7^8 per group).One-way ANOVA
and LSD tests (53 groups), two-tailed t-tests (B and D: 2 groups), two-way ANOVA (B and D: 2 2 comparisons, drug interaction
effects are shown). P50.05/P50.01 compared with vehicle-treated control mice; yP50.05/yyP50.01 compared with animals receiving
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Sugiyama et al., 2003), but not other (Cisternino et al.,
2003; Lee et al., 2004) studies. Unfortunately, earlier studies
strongly focused on ABCC1’s role at the luminal endothelial
membrane. As such, intra-cerebral (Sugiyama et al., 2003)
or intra-cerebroventricular (Nishino et al., 1999; Lee et al.,
2004) drug infusions were mostly used. Moreover, auto-
radiographic techniques were applied for 17bEG and GSNO
measurement (Nishino et al., 1999; Cisternino et al., 2003;
Sugiyama et al., 2003; Lee et al., 2004), which did not
distinguish 17bEG and GSNO from 17bE and glutathione,
to which the molecules were cleaved (17bEG: shown here;
GSNO: see Lee et al., 2004). As a consequence, not the
delivered parent compounds, but their metabolites were
measured in the brain tissue. Methodological limitations
explain the earlier non-specific findings.
Physiological role of ABCC1at the BBB
The substrate affinity to glucuronidated, glutathionized
and sulphated compounds is a characteristic feature of
ABCC1 (Hermann and Bassetti, 2007). These compounds
are so-called phase II degradation products, which have
been metabolized in order to be excreted via the kidneys.
The question arises to which purpose an ABC transporter
accumulates conjugated molecules in the brain. Our observa-
tion that 17bEG uptake went along with elevated 17bE
levels sheds light on this issue, indicating that 17bEG
was deglucuronidated, most likely by b-glucuronidase
(Brooks et al., 2002). b-Glucuronidase is a lysosomal
hydrolase constitutively expressed in the brain that is
deficient in mucopolysaccharidosis VII (Brooks et al.,
2002), a neurodegenerative disorder. Our finding of
17bEG deglucuronidation suggests that ABCC1 enables
17bE recycling, offering the brain the possibility to regenerate
conjugated molecules.
ABCC1 shares its affinity to phase II degradation prod-
ucts with transporters of the solute carrier-21 family, which
are involved in drug uptake into capillary cells (Meier and
Stieger, 2002; Hagenbuch and Meier, 2004). 17bEG and
GSNO are known substrates of solute carrier-21 transpor-
ters, namely of organic anion transporter (Oatp)1a4, which
is expressed at the luminal membrane of brain capillary
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Fig. 6 Inhibition of ABCC1with MK571 reverses 17bEG’s neuroprotective and GSNO’s neurotoxic effects after focal cerebral ischaemia
induced by 90min MCA occlusion. LDF during and after ischaemia (A and D), infarct volume (B and E) and infarct areas at various
rostrocaudal brain levels (C and F) assessed by cresyl violet staining 24h after reperfusion. Note again the absence of blood flow
changes between groups (A and D). Note again that ABCC1 deactivation (here in C57Bl6/j animals) abolishes 17bEG’s and GSNO’s
effects on infarct size (B,C, E and F). Data are means SD (n=6^8 animals per group).One-way ANOVA and LSD tests (A^F),
two-way ANOVA (B and E: 2 2 comparisons, drug interaction effects are shown). P50.05/P50.01 compared with vehicle-treated
mice; yP50.05/yyP50.01 compared with animals receiving 17bEG (10mg kg^1) or GSNO (1mg kg^1) only.
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cells (Gao et al., 1999). That ABCC1 accumulated drugs
in the brain tissue implies that solute carriers were func-
tional. The role of solute carriers in drug biodistribution
will deserve additional attention in the future.
Implications of abluminal ABC transporters
for drug development
That an active transporter contributes to drug accumulation
in the brain following stroke has important clinical impli-
cations. As such, the brain access of drugs may markedly be
improved by chemical modifications resulting in increased
ABCC1 affinity. In view of ABCC1’s strong affinity to con-
jugated molecules, glucuronidation, glutathionization or
sulphatation may render drugs able to pass the BBB. Drug–
protein interactions have gained huge interest in drug
development recently. As such, crystal structures have offered
new insights into the kinetics of drug binding with ABC
transporters (Murakami et al., 2006). Based on our data,
crystal structures might allow the selection of new generations
of drugs that bind to abluminal, but lack interactions
with luminal ABC transporters. This might potently increase
brain accumulation and drug efficacy, and enhance the
overall success of pharmacological therapies.
Supplementary material
Supplementary material is available at Brain online.
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